glp 1 semaglutide or tirzepatide vs for Weight Loss VivioMD GLP-1 Program Overview 2026:

All data were extracted from the electronic medical records and the mobile health app database at NOVI Health and patient consent was waived given its retrospective nature and use of only deidentified data

Ha un effetto sul peso, ma inferiore rispetto alle formulazioni ad alto dosaggio studiate per lobesit

However, availability and insurance coverage often change as medications become more widely used

These often occur within a week of starting semaglutide, though noticeable changes in weight or blood sugar take longer

Key Takeaways Tirzepatide vs semaglutide comes down to dual agonist vs single agonist: tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone The only head-to-head trial (SURPASS-2) found tirzepatide superior to semaglutide for both blood sugar control and weight loss In separate obesity trials, tirzepatide 15mg achieved 20.9% weight loss at 72 weeks vs semaglutide 2.4mg's 14.9% at 68 weeks Semaglutide has proven cardiovascular benefit (SELECT trial: 20% MACE reduction)